SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...

WuXi 2269-0.22%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-0.50%decrease; red down pointing triangle & Co. for half a billion dollars ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A Merck KGaA brand logo stands in front of the company premises. WuXi Biologics, a Chinese biopharmaceuticals company, announced on 06 January the sale of its WuXi Vaccines facility in Ireland to ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Wuxi Biologics ...

WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO), announced an agreement with Candid Therapeutics, Inc. (Candid), a clinical-stage biotechnology ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate.

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...